drugset / Trial / NCT00006220
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
Phase 1/2
Terminated
5 enrolled
Washington University School of Medicine
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells. PURPOSE: Phase I/II trial to study the effectiveness of arsenic trioxide with or without tretinoin in treating patients who have hematologic cancer that has not responded to previous therapy.
Timeline
- Start
- 1999-06
- Primary completion
- 2000-11
- Completion
- 2002-02
Outcome
Outcome not reported
Stopped: “Study drug became commercially available.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tretinoin | Unknown | — | — |
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Intravenous |